Antibiotic Management of Intra‑Abdominal Infections

1. Pathogen Spectrum in Community‑Acquired Mild‑to‑Moderate Disease

• Enteric gram‑negative aerobic/facultative bacilli, chiefly Escherichia coli, account for ~71 % of isolates. [1][4]
• Enteric gram‑positive streptococci are also common pathogens. [1][2]
• Obligate anaerobes of the Bacteroides fragilis group cause ~35 % of distal small‑bowel, appendiceal, and colonic infections. [1][2]4

2. Empiric Regimens for Community‑Acquired Mild‑to‑Moderate Intra‑Abdominal Infections

2.1 Preferred Single‑Agent Options

• Ertapenem 1 g IV q24 h – provides coverage of gram‑negative aerobes, streptococci, and anaerobes. [1][2]3
• Moxifloxacin 400 mg IV q24 h – broad‑spectrum fluoroquinolone with anaerobic activity. [1][2]3
• Tigecycline (100 mg loading dose, then 50 mg IV q12 h) – active against multidrug‑resistant gram‑negatives and anaerobes. [1][2]3
• Cefoxitin 2 g IV q6 h – a second‑generation cephalosporin with reliable anaerobic coverage. 3

2.2 Preferred Combination Options (Metronidazole + a Gram‑Negative Agent)

• Metronidazole 500 mg IV q8‑12 h + Ceftriaxone 1‑2 g IV q12‑24 h. 3
• Metronidazole + Cefotaxime 1‑2 g IV q6‑8 h. 3
• Metronidazole + Cefazolin 1‑2 g IV q8 h. 3
• Metronidazole + Cefuroxime 1.5 g IV q8 h. 3
• Metronidazole + Levofloxacin 750 mg IV q24 h. 3
• Metronidazole + Ciprofloxacin 400 mg IV q12 h. 3

3. Empiric Regimens for High‑Severity or Critically Ill Patients

• Piperacillin‑tazobactam 3.375 g IV q6 h (or 4.5 g q6 h for suspected Pseudomonas). 7
• Imipenem‑cilastatin 500 mg IV q6 h or 1 g IV q8 h. 5
• Meropenem 1 g IV q8 h. 5
• Doripenem 500 mg IV q8 h. 5
• Cefepime 2 g IV q8‑12 h + Metronidazole 500 mg IV q8‑12 h. 3

4. Healthcare‑Associated Intra‑Abdominal Infections

4.1 Guiding Principle

• Empiric therapy must be tailored to local antibiograms because of frequent ESBL‑producing Enterobacteriaceae, resistant Pseudomonas aeruginosa, Acinetobacter, and MRSA. [5][6]7

4.2 Non‑Critically Ill Patients

• First‑line: Piperacillin‑tazobactam 4.5 g IV q6 h. 8
• If ESBL prevalence ≥20 % or recent antibiotic exposure: Carbapenem (Meropenem 1 g IV q8 h, Doripenem 500 mg IV q8 h, or Imipenem‑cilastatin 1 g IV q8 h). [5][6][7][8]

4.3 Critically Ill Patients

• Carbapenem‑based regimens preferred: Meropenem, Doripenem, or Imipenem‑cilastatin at standard dosing. [5][6][7][8]
• Add vancomycin (15‑20 mg/kg IV q8‑12 h) when institutional MRSA prevalence ≥20 %. [5][6][7][8]
• Add an echinocandin (e.g., caspofungin 70 mg loading then 50 mg daily) for patients at high risk of invasive candidiasis (recent abdominal surgery, anastomotic leak, necrotizing pancreatitis, or poor response to antibacterial therapy). 8

5. Agents to Avoid (Critical Pitfalls)

• Ampicillin‑sulbactam – high resistance among community E. coli (>20 %). [5][6][7][1][2][4]3
• Cefotetan or clindamycin – rising resistance in the Bacteroides fragilis group. [5][6][7][1][2][4]3
• Aminoglycosides for routine community‑acquired intra‑abdominal infections – less toxic alternatives are equally effective. [5][6][7][1][2][4]3

6. When Not to Provide Routine Coverage

• Enterococcus – empiric coverage unnecessary in community infections unless the patient is immunocompromised, has recent antibiotic exposure, or receives a regimen lacking Enterococcus activity. [5][6][7][1][2][4]3
• Candida – empiric antifungal therapy is not recommended for community‑acquired intra‑abdominal infections. [5][6][7][1][2][4]3

7. Fluoroquinolone Use Restrictions

• Ciprofloxacin and levofloxacin should be avoided when local E. coli resistance exceeds 10‑20 %. [2][3]

8. Special Considerations – Biliary Infections

• Mild‑to‑moderate cholecystitis: Cefazolin, Cefuroxime, or Ceftriaxone are appropriate empiric agents. [5][6]7
• Severe cholecystitis or cholangitis with bilio‑enteric anastomosis: Choose a carbapenem or piperacillin‑tazobactam or a fluoroquinolone/cefepime plus metronidazole. [5][6]7

9. Duration of Therapy

• Typical treatment course is 4–7 days when adequate source control is achieved; courses >8 days increase the risk of multidrug‑resistant organism development. [5][6]7

10. Culture‑Directed Management

• Obtain intra‑operative cultures in high‑risk patients (prior antibiotic exposure, healthcare‑associated infection, severe illness) and perform susceptibility testing for Pseudomonas, Proteus, Acinetobacter, Staphylococcus aureus, and predominant Enterobacteriaceae. [5][6][9][7]
• De‑escalate antimicrobial therapy based on culture and susceptibility results once available. [5][6][9][7]